Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 97Observational 1Expanded_access 1

Sponsor

Cancer Type

Thoracic 12Other solid neoplasm 1Other 1CNS 1

Conditions

Mesothelioma, Malignant 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Blood Specimen Collection 8Surveys and Questionnaires 7Fluorodeoxyglucose F18 4larotrectinib 3Magnetic Resonance Imaging 3Data Collection 3envafolimab 2Watchful Waiting 2Specimen Handling 2Quality of Life 2Psychiatric Rehabilitation 2Microarray Analysis 2Immunoenzyme Techniques 2Histocompatibility Testing 2Genetic Testing 2Gene Expression Profiling 2Fluorouracil 2Drug Therapy 2Blood Component Removal 2trifluridine tipiracil drug combination 1tegafur-gimeracil-oteracil 1etoposide phosphate 1disitamab vedotin 1alovudine 1Wechsler Scales 1Vascular Endothelial Growth Factor A 1Tumor Burden 1Tomography, Optical Coherence 1Tomography, Emission-Computed 1Tissue Banks 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Pemetrexed × Other solid neoplasm × Clear all
NCT04843007 2024-10-23

Alvopem® (Pemetrexed) Safety Assessment

NanoAlvand

Completed
199 enrolled 21 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡